AR and prostate carcinoma: Preclinical pharmacology studies have demonstrated that enzalutamide competitively inhibits androgen-induced receptor activation, nuclear translocation of activated androgen receptors, and the association of the activated androgen receptor with chromatin, even in the setting of androgen receptor over-expression and in prostate cancer cells resistant to anti-androgens [17].